InvestorsHub Logo
Followers 56
Posts 6361
Boards Moderated 0
Alias Born 03/25/2015

Re: None

Tuesday, 11/27/2018 12:54:31 PM

Tuesday, November 27, 2018 12:54:31 PM

Post# of 330240
RECOVERYRX 510(K) FROM THE PRESS RELEASE

Sree Koneru, VP of Product Development, expressed confidence in this strategy, both from a regulatory and marketability perspective. “We are also diligently proceeding with 510(k) applications for US market clearance of postoperative pain (RecoveryRx®) and menstrual pain (Allay®),” he added.

BIEL applied 2 510(K)s about the same time in JULY-AUG.

https://globenewswire.com/news-release/2018/11/27/1657557/0/en/BioElectronics-Announces-FDA-Market-Clearance-Update.html